Want to see AU:MAP full AI Analyst Report?
MAP Stock Chart & Stats
AU$0.04
<AU$0.01(2.22%)
At close: 4:00 PM EDT
AU$0.04
<AU$0.01(2.22%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.11
Previous CloseN/A
Volume296.78K
Average Volume (3M)469.77K
Market Cap
AU$32.21M
Enterprise ValueAU$35.84
Total Cash (Recent Filing)AU$11.27M
Total Debt (Recent Filing)AU$3.31M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 01, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding700,307,500
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.09Price Target Upside112.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$22.25M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseA low debt-to-equity ratio of 0.10 indicates limited financial leverage, giving Microba flexibility to fund R&D, partnerships or working capital without high interest burdens. This reduces refinancing risk and supports resilience while the business scales toward profitability.
Positive Free Cash Flow GrowthFCF growth of 4.68% and FCF exceeding net income show the company can generate cash beyond accounting losses. That supports continued operations, funds selective investments or collaborations, and extends runway without immediate reliance on equity issuance or heavy debt.
Platform And Diversified Revenue StreamsMicroba's integrated microbiome platform spans clinical testing, B2B research services and therapeutics discovery. This multi-pronged model creates multiple durable revenue channels, allows cross-selling, and positions the company to capture long-term demand for microbiome measurement and drug development support.
Bears Say
Declining Revenue TrendA steep revenue decline (‑24.28%) undermines operating leverage and the company’s ability to spread fixed costs. Sustained top-line contraction makes achieving scale economics harder, pressures margins and limits internal funding capacity for R&D and commercial expansion over months to quarters.
Negative Operating Cash FlowPersistent negative operating cash flow means core operations are not generating sufficient cash, forcing reliance on financing or reserve funds. This constrains investment in commercialization and partnerships and increases execution risk until operations generate positive cash.
Ongoing Losses And Negative ReturnsNegative profitability and ROE indicate the business has yet to achieve sustainable margins. Continued losses erode equity value and hamper reinvestment capacity, making it harder to attract partners or scale commercial offerings without clear progress toward profitability.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$32.21M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Sep 01, 2026 which is in 33 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate is >-0.01.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 700,307,500 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.09 (112.50% Upside)
AU$0.09 (112.50% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.63%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.09
▲(112.50% Upside)
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―